Safety, Tolerability, and Pharmacokinetics of Mevidalen (LY3154207), a Centrally Acting Dopamine D1 Receptor‐Positive Allosteric Modulator (D1PAM), in Healthy Subjects - Wilbraham, Darren; Biglan, Kevin M.; Svensson, Kjell A.; Tsai, Max; Kielbasa, William (Clinical pharmacology in drug development, 2021)
Keywords: Administration, Oral; Adolescent; Adult; Aged; Allosteric Regulation - drug effects; Blood pressure; Blood Pressure - drug effects; Cohort Studies; Dopamine; Dopamine Agents - administration & dosage; Dopamine Agents - pharmacokinetics; Dopamine Agents - pharmacology; Dose-Response Relationship, Drug; Double-Blind Method; Female; Heart Rate - drug effects; Humans; Isoquinolines - administration & dosage; Isoquinolines - pharmacokinetics; Isoquinolines - pharmacology; Male; mevidalen (LY3154207); Middle Aged; Original Manuscript; Pharmacokinetics; Receptors, Dopamine D1 - drug effects; Receptors, Dopamine D1 - metabolism; safety; tolerability; Young Adult; pharmacokinetics; dopamine; mevidalen (LY3154207); safety; tolerability